← 返回

病例报告:复发/难治性侵袭性 B 细胞淋巴瘤患者 CAR-T 细胞治疗后的急性 HHV6B 脑炎/脊髓炎

英文原题:Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma.

查看英文原题

Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma.

PubMed 2024/02/29(内容时间) Front Neurol Q2 · IF 3.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

鉴于其致命潜力,CAR-T 细胞治疗后应紧急诊断 HHV6B 脑炎/脊髓炎。此外,血液科医生应尽早将这些情况与 CRS 或其他免疫治疗相关神经毒性进行鉴别诊断。本研究结果表明,mNGS 在 HHV6B 感染早期诊断中具有潜力,尤其是当该微生物难以培养时。

研究思路结论见上方概要

嵌合抗原受体(CAR)-T细胞疗法的发展彻底改变了淋巴系统恶性肿瘤患者的治疗结局。然而,多项研究报告显示,成人患者在接受靶向CD19的CAR-T 细胞治疗后感染率相对较高,尤其是在最初28天内。值得注意的是,急性人类疱疹病毒6B(HHV6B)再激活在异基因造血干细胞移植患者中发生率高达三分之二。病例报告:本文报告了三例复发/难治性弥漫性大B细胞淋巴瘤患者在接受CAR-T 细胞治疗后发生HHV6B脑炎/脊髓炎的情况。三例患者均接受过多线既往治疗(范围:2-9线)。所有患者在CAR-T 细胞输注(CTI)后均出现持续至少2周的发热。其发生时间和持续时间均与细胞因子释放综合征(CRS)相似;然而,患者的CRS分级较低(1级或2级)。CTI后出现谵妄和记忆丧失是最早值得注意的精神表现。神经系统表现迅速进展,患者出现不同程度的意识障碍、癫痫发作和昏迷。患者3还观察到背痛、腰痛、下肢无力和尿潴留,提示脊髓炎。通过宏基因组下一代测序(mNGS)在所有脑脊液(CSF)样本中均检测到高HHV6B载量。仅一例患者需要高活性抗病毒药物和IgG静脉冲击治疗并最终康复,而另外两例患者死于HHV6B脑炎。

展开英文摘要原文

The development of chimeric antigen receptor (CAR)-T cell therapy has revolutionized treatment outcomes in patients with lymphoid malignancies. However, several studies have reported a relatively high rate of infection in adult patients following CD19-targeting CAR T-cell therapy, particularly in the first 28 days. Notably, acute human herpesvirus 6 B (HHV6B) reactivation occurs in up to two-thirds of allogeneic hematopoietic stem cell transplantation patients. CASE PRESENTATIONS: Herein, we describe a report of HHV6B encephalitis/myelitis in three patients with relapsed/refractory diffuse large B-cell lymphoma post CAR T-cell therapy. All three patients received multiple lines of prior treatment (range: 2-9 lines). All patients presented with fever that persisted for at least 2 weeks after CAR-T cell infusion (CTI). Both the onset time and duration were similar to those of the cytokine release syndrome (CRS); nevertheless, the CRS grades of the patients were low (grade 1 or 2). Delirium and memory loss after CTI were the earliest notable mental presentations. Neurological manifestations progressed rapidly, with patients experiencing varying degrees of impaired consciousness, seizures, and coma. Back pain, lumbago, lower limb weakness and uroschesis were also observed in Patient 3, indicating myelitis. High HHV6B loads were detected in all Cerebral spinal fluid (CSF) samples using metagenomic next-generation sequencing (mNGS). Only one patient required high-activity antivirals and IgG intravenous pulse treatment finally recovered, whereas the other two patients died from HHV6B encephalitis.

Considering its fatal potential, HHV6B encephalitis/myelitis should be urgently diagnosed post CAR-T cell-based therapy. Furthermore, hematologists should differentially diagnose these conditions from CRS or other immunotherapy-related neurotoxicities as early as possible. The results of this study demonstrate the potential of mNGS in the early diagnosis of HHV6B infection, particularly when the organism is difficult to culture.

论文信息

作者
Li N、Zhang R、Wang J、Zhu X、Meng F、Cao Y、Wang G、Yang Y
单位
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.China
文献类型
病例报告
期刊
Frontiers in neurology2024
原文标识
PubMed 38487325 · DOI 10.3389/fneur.2024.1334000